Clinical trials: Psychotic Symptoms
Schizophrenia
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
- Trial name
- NCT01738698
- Testing
- SPD489 40mg, SPD489 100mg, SPD489 160mg
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shire
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
C-Cog in Early Course Schizophrenia Study
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
- Trial name
- NCT05662306
- Testing
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Schizophrenia, Schizoaffective Disorder
Sulforaphane to Reduce Symptoms of Schizophrenia
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
- Trial name
- NCT02810964
- Testing
- Sulforaphane Nutraceutical
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Sheppard Pratt Health System
Major Depressive Disorder With Psychotic Features
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.
- Trial name
- Seroquel (NCT00955474)
- Testing
- Quetiapine, escitalopram, Sertraline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Clinical Trial of Dipyridamole in Schizophrenia
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00349973
- Testing
- Dipyridamole, Olanzapine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Maryland, Baltimore
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and…
- Conditions
- Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders
- Trial name
- Jade (NCT00561574)
- Testing
- Esmirtazapine
- Volunteers
- 259 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Psychosis
The Relationship Between Autobiographical Memory and Motivation
People with a diagnosis of psychosis often experience low motivation and pleasure when thinking about doing future activities. This leads, quite understandably, to doing fewer activities they used to enjoy and not taking up…
- Trial name
- NCT03677635
- Testing
- Guided Autobiographical Memory Recall
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- King's College London
Care Burden, Care Giving Burden
Altitudes: A Digital Intervention to Support Caregivers
The purpose of the present study is to investigate the feasibility, accessibility, and potential clinical benefits of implementing a moderated online social media platform with therapeutic content, Altitudes, to parents…
- Conditions
- Care Burden, Care Giving Burden, Caregiver Burnout, Caregiver Stress
- Trial name
- NCT06509100
- Testing
- Device: Altitudes USA
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Depression
Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT
The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during…
- Trial name
- NCT00285818
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Patients With Schizophrenia and Acute Agitation
Staccato Loxapine in Agitated Patients With Schizophrenia
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
- Trial name
- NCT00628589
- Testing
- Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
An Open-Label Trial of Tocilizumab in Schizophrenia
This study is a Phase 1 clinical trail to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia.
- Trial name
- NCT01696929
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brian Miller
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill